GlassScriptPhysician profile
Andrew Defilippis
NPI 1316969876
$5,721.27
in general payments reported to CMS, 2019-2025
11 companies · $393 in 2025
The $393 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $116 · 2022: $265 · 2023: $176 · 2024: $4,021 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,100 · Food and Beverage: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,100.00 |
| Food and Beverage | $1,489.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,395.42 | 2024-2025 | |
| Abiomed | $1,099.89 | 2019-2025 | Impella |
| Boston Scientific Corporation | $412.07 | 2019-2024 | Watchman |
| Radiometer America, INC | $250.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $204.95 | 2019 | |
| Inari Medical, INC. | $137.01 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Edwards Lifesciences Corporation | $125.43 | 2022 | |
| Philips North America LLC | $75.59 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.91 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Defilippis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.